Czaja A
Clin Liver Dis (Hoboken). 2020; 15(Suppl 1):S72-S81.
PMID: 32140216
PMC: 7050953.
DOI: 10.1002/cld.917.
Lammert C
Clin Liver Dis (Hoboken). 2019; 14(1):29-32.
PMID: 31391934
PMC: 6677013.
DOI: 10.1002/cld.798.
Lammert C, McKinnon E, Chalasani N, Phillips E
Clin Transl Gastroenterol. 2019; 10(6):e00032.
PMID: 31211758
PMC: 6613860.
DOI: 10.14309/ctg.0000000000000032.
Gershwin M, Krawitt E
Hepatology. 2014; 59(3):754-6.
PMID: 24712041
PMC: 3980492.
DOI: 10.1002/hep.26682.
Zhang W, Zhao F, Chen J, Chen W
PLoS One. 2014; 9(3):e92267.
PMID: 24651126
PMC: 3961308.
DOI: 10.1371/journal.pone.0092267.
A 50-year experience with autoimmune hepatitis: and where are we now?.
Mackay I
J Gastroenterol. 2010; 46 Suppl 1:17-28.
PMID: 21072544
DOI: 10.1007/s00535-010-0325-2.
The concept of autoimmune liver disease.
Mackay I
Bull N Y Acad Med. 2009; 52(4):453-65.
PMID: 19312943
PMC: 1807167.
Historical reflections on autoimmune hepatitis.
Mackay I
World J Gastroenterol. 2008; 14(21):3292-300.
PMID: 18528926
PMC: 2716583.
DOI: 10.3748/wjg.14.3292.
Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis.
Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M
Dig Dis Sci. 1998; 43(10):2190-5.
PMID: 9790453
DOI: 10.1023/a:1026650118759.
Autoimmune hepatitis. Definition--classification--histopathology--immunopathogenesis.
Meyer zum Buschenfelde K, Dienes H
Virchows Arch. 1996; 429(1):1-12.
PMID: 8865847
DOI: 10.1007/BF00196814.
Comparison of the clinical and immunogenetic features between patients with autoimmune hepatitis and patients with type C chronic active hepatitis.
Kiyosawa K, Seki T, Tanaka E, Sodeyama T, Furuta K, Furuta S
Gastroenterol Jpn. 1993; 28 Suppl 4:63-8; discussion 76-80.
PMID: 8486232
DOI: 10.1007/BF02782892.
Autoimmune hepatitis. Evolving concepts and treatment strategies.
Czaja A
Dig Dis Sci. 1995; 40(2):435-56.
PMID: 7851212
DOI: 10.1007/BF02065434.
Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial.
Van Thiel D, Wright H, Carroll P, Abu-Elmagd K, McMichael J, Irish W
Am J Gastroenterol. 1995; 90(5):771-6.
PMID: 7537444
PMC: 3022515.
Liver disease and the e antigen in HBsAg carriers with chronic renal failure.
Coughlin G, Van Deth A, Disney A, Hay J, WANGEL A
Gut. 1980; 21(2):118-22.
PMID: 7380332
PMC: 1419355.
DOI: 10.1136/gut.21.2.118.
HLA types in liver disease in the West of Ireland.
Kiernan T, Stevens F, Bourke M, McCarthy C
Ir J Med Sci. 1980; 149(2):63-5.
PMID: 7372450
DOI: 10.1007/BF02939113.
Jejunal villous changes associated with farmer's lung.
Robinson T, Nelson S, Haire M, Middleton D, McMillan S, Evans J
Postgrad Med J. 1981; 57(673):697-701.
PMID: 7339601
PMC: 2426187.
DOI: 10.1136/pgmj.57.673.697.
Interaction of HLA and Gm in autoimmune chronic active hepatitis.
Whittingham S, Mathews J, Schanfield M, Tait B, Mackay I
Clin Exp Immunol. 1981; 43(1):80-6.
PMID: 7249397
PMC: 1537131.
Immunologic effector mechanisms in hepatitis B-negative chronic active hepatitis.
Klingenstein R, Wands J
Springer Semin Immunopathol. 1980; 3(3):317-29.
PMID: 7022713
DOI: 10.1007/BF02054107.
Genetic determinants of autoimmune chronic active hepatitis.
Mackay I, Whittingham S, Mathews J, Tait B
Springer Semin Immunopathol. 1980; 3(3):285-96.
PMID: 7022711
DOI: 10.1007/BF02054105.
Association of primary sclerosing cholangitis with HLA-B8.
Chapman R, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S
Gut. 1983; 24(1):38-41.
PMID: 6600227
PMC: 1419910.
DOI: 10.1136/gut.24.1.38.
